LabGenius Appoints Dr Edwin Moses as Chairman of its Board of Directors -- LabGenius ML-Driven Protein Evolution

London, UK 20 April 2020 – LabGenius Ltd ("LabGenius" or "the Company"), a biopharmaceutical company developing next-generation protein therapeutics using machine learning, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors. Edwin Moses was Chief Executive Officer of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018. He was CEO of Ablynx for more than 12 years and built it from a small R&D-focused organisation into a 500-person commercial-ready business. The company developed a broad biologics pipeline including a wholly-owned product for a rare hematologic indication, which was approved for use in Europe in 2018 and the USA in 2019. While at Ablynx, Dr Moses led its Euronext Brussels listing, multiple successful private and public financings and its US NASDAQ listing in 2017 which raised $230M.